[Oxalosis].
Cordonnier C, Noel C, Gosselin B.
Ann Pathol. 1995;15(6):415-23.
[OXALOSIS].
MAZZEO G.
Lattante. 1964 Jul;35:357-71.
Management of oxalosis.
Broyer M, Jouvet P, Niaudet P, Daudon M, Revillon Y.
Kidney Int Suppl. 1996 Jan;53:S93-8.
AJKD Atlas of Renal Pathology: Oxalosis.
Fogo AB, Lusco MA, Najafian B, Alpers CE.
Am J Kidney Dis. 2017 Mar;69(3):e13-e14. doi: 10.1053/j.ajkd.2017.01.006.
Bone marrow oxalosis with pancytopenia in a patient with short bowel syndrome: Report of a case and review of the literature.
Bering JL, Wiedmeier-Nutor JE, Sproat L, DiBaise JK.
JPEN J Parenter Enteral Nutr. 2023 Jan;47(1):165-170. doi: 10.1002/jpen.2453. Epub 2022 Oct 17.
Oxalosis.
KATZUNI E, SANDBANK U.
Arch Dis Child. 1959 Feb;34(173):60-2. doi: 10.1136/adc.34.173.60.
Cutaneous Oxalosis Due to Primary Hyperoxaluria.
Ly S, Rick J, Goff R, David BA, Kincannon J, Shalin S.
Am J Dermatopathol. 2022 Dec 1;44(12):981-983. doi: 10.1097/DAD.0000000000002307.
Diagnosis and management of primary hyperoxalurias: best practices.
Michael M, Harvey E, Milliner DS, Frishberg Y, Sas DJ, Calle J, Copelovitch L, Penniston KL, Saland J, Somers MJG, Baum MA.
Pediatr Nephrol. 2024 Nov;39(11):3143-3155. doi: 10.1007/s00467-024-06328-2. Epub 2024 May 16.
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O'Riordan WD, Cochat P, Deschênes G, Shasha-Lavsky H, Saland JM, Van't Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnaw AK, Gansner JM, McGregor TL, Lieske JC; ILLUMINATE-A Collaborators.
N Engl J Med. 2021 Apr 1;384(13):1216-1226. doi: 10.1056/NEJMoa2021712.
Pathophysiology and Management of Hyperoxaluria and Oxalate Nephropathy: A Review.
Demoulin N, Aydin S, Gillion V, Morelle J, Jadoul M.
Am J Kidney Dis. 2022 May;79(5):717-727. doi: 10.1053/j.ajkd.2021.07.018. Epub 2021 Sep 9.
